January 24, 2020Open Access

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

Key Points

Key points are not available for this paper at this time.

Abstract

Cisplatin and gemcitabine is an effective regimen in advanced gBRCA/PALB2+ PDAC. Concurrent veliparib did not improve RR. These data establish cisplatin and gemcitabine as a standard approach in gBRCA/PALB2+ PDAC.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Eileen M. O’Reilly

Northwestern University

Jonathan W. Lee

NewYork–Presbyterian Hospital

Mark M. Zalupski

University of Michigan

Journals

Journal of Clinical Oncology

Actions

Institutions

University of Michigan

University of Chicago

Memorial Sloan Kettering Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study